Tort

Weight-Loss Drug Manufacturers Strategize Defenses Learning From U.S. Mass Tort Litigation History

by

Washington, D.C. – As the pharmaceutical landscape evolves, manufacturers of popular GLP-1 weight-loss drugs find themselves at a crossroads, facing potential legal challenges reminiscent of previous cases in the U.S. pharmaceutical history. These companies, harnessing the attributes of the glucagon-like peptide-1 receptor agonists, must draw on lessons from past litigation to strategically fortify themselves against similar future challenges. Manufacturers are currently benefiting from a surge in the popularity of these drugs, lauded for their effectiveness in weight management. The increasing prevalence of obesity across the country has driven demand, positioning GLP-1 receptor agonists as key … Read more

Supreme Court Restricts Nonconsensual Releases in Chapter 11 Bankruptcies, Impacting Mass Tort Litigation

by

Washington, D.C. – In a significant ruling that may transform the landscape of bankruptcy law, the U.S. Supreme Court has decisively limited the use of “nonconsensual third-party releases” in chapter 11 reorganization plans. This decision, falling on a narrow 5-4 margin, rejected these provisions, which previously allowed for the involuntary release of claims against nondebtors, such as the controversial inclusion of the Sackler family in Purdue Pharma’s bankruptcy case. Delivering the majority opinion, Justice Neil Gorsuch, joined by Justices Clarence Thomas, Samuel Alito, Amy Coney Barrett, and Ketanji Brown Jackson, articulated that such releases improperly … Read more

Exploring the Dynamics of Mass Tort Leads Costs in 2024: What Legal Professionals Need to Know

by

New York — As 2024 progresses, the legal industry is observing a significant uptick in the cost of mass tort leads, a crucial component for law firms specializing in class action suits and multi-district litigation. This change not only affects the way law firms budget for and manage large-scale cases but also highlights emerging trends in the industry, including increased competition and technological advancements. Mass tort cases, known for consolidating numerous plaintiffs against one or several corporate defendants, are inherently complex and expensive to litigate. They often involve intricate legal arguments and extensive evidence gathering, … Read more

Expert Raises Alarm: Purdue Pharma Case May Reshape Future Mass Tort Litigations

by

Stamford, Connecticut – The recent resolution of the Purdue Pharma bankruptcy case has sparked a vigorous debate about the implications of mass tort cases involving major corporations. The settlement, which absolves the Sackler family from future opioid-related lawsuits while they remain major stakeholders in the restructured company, underscored contentious issues regarding accountability and compensation in similar legal battles across the United States. Critics argue that the outcome sets a precedent that may allow wealthy individuals and entities to circumvent full accountability by using bankruptcy courts to shield their assets. Legal experts have raised concerns about … Read more